CDOCKET NO.: BMS-0891/PH-7345-A

NO.: BMS-0891/PH-7345-7. IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CEIVED OCT 2 9 2003 TECH CENTER 1600/2900

In Re Application of:

James R. McCarthy **Application No.: 09/995,159**

Group Art Unit: 1624

Filing Date: November 27, 2001

Examiner: V. Balasubramanian

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

EXPRESS MAIL LABEL NO: EL 970385364 US

DATE OF DEPOSIT: October 9, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

 \boxtimes In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for
continued examination under § 1.114, no additional fee is required.
In accordance with § 1.129(a), this Information Disclosure Statement is being
filed in connection with the first or second After Final Submission,
therefore:
Certification in Accordance with § 1.97(e) is attached; or
The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
In accordance with § 1.97(c), this Information Disclosure Statement is being
filed after the period set forth in § 1.97(b) above but before the mailing date of
either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or
before an action that otherwise closes prosecution in the application, therefore:
Certification in Accordance with § 1.97(e) is attached
or
The fee of \$180.00 as set forth in § 1.17(p) is attached.
In accordance with § 1.97(d), this Information Disclosure Statement is being
filed after the mailing date of either a Final Action under § 1.113 or a Notice
of Allowance under § 1.311 but before, or simultaneously with, the payment
of the Issue Fee, therefore included are: Certification in Accordance with §
1.97(e); and the submission fee of §180.00 as set forth in § 1.17(p).
Copies of each of the references listed on the attached Form PTO-1449 are
enclosed herewith.

DOCKET NO.: BMS-0891/PH-7345-A - 3 -

PATENT

Copies of references listed on the attached Form PTO-1449 are enclosed herewith

Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- In view of the voluminous nature of reference number 37, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:
 - Copies of references 1-8 and 51-52 listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. 09/415,503 now U.S. Patent No. 6,352,990, filed October 8, 1999.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

DOCKET NO.: BMS-0891/PH-7345-A - 4 - PATENT

The relevance of those	listed references	which are	e not in the	English languag	ge is as
follows:					

There are no listed references which are not in the English language.

Date:

S. Maurice Valla

Registration No. 43,966

WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2003 WW





Form P	Form PTO-1449 Modified			o. 1/PH-7345-A	Application No. 09/995,159	PFCEIVE
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant James R.	McCarthy, et a	1.	PFCEIVE 0CT 2 0 2003 TEUM UENTER 1600/29	
	U.S. Department of Commerce Patent and Trademark Office			te r 27, 2001	Group 1624	
			Confirma 1709	tion No.		
OT	HER	R DOCUMENTS (Inclu	ding Autho	r, Title, Date,	Pertinent Pages, E	tc.)
	1	Adamiak, et al., Angew	. Chem., 198	5 , <i>97(12)</i> , 1040	6 (CA 104:110099,	1986)
	2	Brown, et al., J. Chem.	Soc., 1969, 0	C18, 2620-262	4 (CA 72:21662, 19	970)
3 Gundersen, et al., Tetrah			hedron Letts	., 1994, 50(32)	, 9743-9756	
	4 Hamann, et al., Can. J. C			, <i>46(3)</i> , 419-42	23 (CA 68:68957, 1	968)
	5	J. Heterocycl. Chem., 1	968 , <i>5(5)</i> , 67	9-682 (CA 70:	:4052, 1969)	
	6	McKenzie, et al., J. Org	g. Chem., 198	32 , <i>47(25)</i> , 488	31-4884	-
	7	Stevenson, et al., Tetral	hedron Letts.	, 1996, 37(46)	, 8375-8378	
	8	Wang, et al., Biochem.	Pharmacol.,	1979 , <i>28(15)</i> , <i>2</i>	2249-2260 (CA 92:	(69336, 1980)
	9	Al-Shaar. AH., et al., reactions of 4- and 5-and 2789-2793				
10 Balicki, R., et al., Transl induced rearrangement of Chem., 1983, 48(1), 3-7			of 4-substitu			
EXAMINER			-	DATE CON	SIDERED	



OCT 2 0 2003

TECH CENTER 1600/2900

Sheet 2 of 7

W THE					
Form PTO	-1449 Modified	Docket No. BMS-0891/PH-7345-A	Application No. 09/995,159		
· · · · · · · · · · · · · · · · ·		Applicant James R. McCarthy, et al.			
	nent of Commerce Frademark Office	Filing Date November 27, 2001	Group 1624		
		Confirmation No. 1709			
ОТНЕ	R DOCUMENTS (Includ	ing Author, Title, Date, l	Pertinent Pages, Etc.)		
11		ise activity in the rat centra	phin-releasing factor receptoral nervous system," Synapse, Alan		
12	Bilezikjian, L.M., et al., "Glucocorticoids inhibit corticotrophin-releasing factor-induced production of adenosine 3',5'-monophosphate in cultured anterior pituitary cells," <i>Endocrinology</i> , 1983 , <i>113(2)</i> , 657-662				
13	Boger, D.L., et al., "Inverse electron demand diels-alder reactions of heterocyclic aza dienes. Studies on the total synthesis of lavendamycin: investigative studies on the preparation of the CDE β -carboline ring system and AB quinoline-5,8-quinone ring system," <i>J. Org. Chem.</i> , 1985 , <i>50</i> (26), 5782-5789				
14		w method for the methyla	tion of amines," J. Org. Chem.,		
15	Brown, M.R., et al., "Con		r: actions on the sympathetic 1982, 111(3), 928-931		
16	Brown, et al., "Corticotro system and oxygen consu	opin-releasing factor: effect amption," <i>Life Sciences</i> , 19	ets on the sympathetic nervous 982 , <i>30</i> , 207-210		
17	receptor," PNAS, USA, C	Chen, R., et al., "Expression cloning of a human corticotrophin-releasing-factor receptor," <i>PNAS, USA</i> , October 1993 , <i>90</i> , 8967-8971			
18	Cheng, YC., et al., "Relationship between the inhibition constant (K_1) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction," <i>Biochem. Pharmacol.</i> , 1973 , 22, 3099-3108				
19	Chatani, N., et al., "Palla cyanide with acetylenes. bonds," <i>J. Org. Chem.</i> , 1	dium- and nickel-catalyze Addition of trimethysilyl (988, 53, 3539-3548	d reaction of trimethylsilyl cyanide to the carbon-carbon triple		
20		thetic method for formyl etrahedron Letts., 1972, 3	→ ethynyl conversion (RCHO → 6, 3769-3772		
EXAMINER		DATE CONS	SIDERED		



OCT 2 0 2003

TECH CENTER 1600/2900

Sheet 3 of 7

Form PTO	Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary)). 1/PH-7345-A	Application No. 09/995,159
Cited b			Applicant James R. McCarthy, et al.	
-	nent of Commerce Frademark Office	Filing Date November		Group 1624
		Confirmat 1709	ion No.	
ОТНЕ	R DOCUMENTS (Includ	ding Author	, Title, Date, 1	Pertinent Pages, Etc.)
21			-	phin-releasing hormone in the Clin. Invest., December 1992, 90,
22	DeSouza, E.B., "Role of corticotrophin-releasing factor in neuropsychiatric disorders and neurodegenerative diseases," <i>Ann. Reports in Med. Chem.</i> , 1990 , <i>25</i> , <i>Chapter 23</i> 215-223			
23	DeSouza, E.B., et al., "Corticotropin-releasing factor receptors in the pituitary gland and central nervious system: methods and overview," <i>Methods Enzymol.</i> , 1986 , <i>124</i> , 560-590			
24	DeSouza, E.B., et al., "Cautoradiographic identifications and the second			or receptors in rat forebrain 4, 224(4656, 1449-1451
25	DeSouza, E.B., et al., "Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution," <i>J. of Neuroscience</i> , January 1987 , 7(1), 88-100			
26	Ehlers, C.L., et al., "Cor	ticotropin re		produces increases in brain Res., 1983, 278, 332-336
27				
28	arerial pressure and hear	t rate in rats	," Endocrinolo	(CRF): Central effects on mean egy, 1982 , 110(6), page 2222
29	methyltransferases. 8. M	Iolecular dis	sections of car	enosylmethionine-dependent bocyclic 3-deazaadenosine as J. Org. Chem., 1985, 28, 467-471
30		ctivates auto	nomic nervou	s system and reduces natural killer
EXAMINER			DATE CON	SIDERED



MFCEIVED

OCT 2 0 2003 TECH CENTER 1600/2900

Sheet 4 of 7

Form 1	PTO	-1449 Modified	Docket No. BMS-0891/PH-7345-A	Application No. 09/995,159	
C	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant James R. McCarthy, et al.		
		nent of Commerce Trademark Office	Filing Date November 27, 2001	Group 1624	
			Confirmation No. 1709		
• 0′	THE	R DOCUMENTS (Includ	ing Author, Title, Date,	Pertinent Pages, Etc.)	
	31	compounds with nucleop halogenopyridazines into	ohiles (XXXVI). Conversion pyrazoles and of 4-amino	ions of heterocyclic halogeno on of 4-amino-3- o-3,6-dihalogenopyridazines into Soc., August 1974, 93(8), 236-	
	32		e synthesis of imidazo [4,5-c]-, s-triazolo [4,3-b]-, and zines," J. Heterocyclic Chem., February 1964, 1(1), 42-47		
	33	•	•	ed corticotrophin releasing factor macology, 1983, 22(3A), 337-339	
	34		GAND: A versatile compudible binding systems," <i>Anal</i> .	terized approach for Biochem., Academic Press, Inc.	
	35	Perrin, M.H., et al., "Cor receptor is modulated by 1986 , <i>118(3)</i> , 1171-1179	divalent cations and guan	or binding to the anterior pituitary yl nucleotides," <i>Endocrinology</i> ,	
	36		ning and functional expreseceptor," <i>Endo.</i> , 1993, 133	ssion of a rat brain corticotrophin (6), 3058-3061	
	37	Remington's Pharmaceu <i>PA</i> , 1990	tical Science, Gennaro (Ed	1.), Mack Publishing Co., Easton,	
	38	Rivier, J., et al., "Charac	terization of rat hypothala. J. Sci. USA, August 1983,	mic corticotrophin-releasing 80, 4851-4855	
	39	Rivier, J., et al., "Synthet	tic competitive antagonists	s of corticotrophin-releasing ce, May 1984, 224(4651), 889-89	
	40	Sapolsky, R., et al., "Inte	rleukin-1 stimulates the so factor," Science, October 2	ecretion of hypothalamic	
XAMINER	L	,	DATE CON		

^{*} A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.



OCT 2 0 2003

TECH CENTER 1600/2900

Sheet 5 of 7

Form PTO	-1449 Modified	Docket No. BMS-0891/PH-7345-A	Application No. 09/995,159		
Cited b	7 11		Applicant James R. McCarthy, et al.		
	nent of Commerce Frademark Office	Filing Date November 27, 2001	Group 1624		
		Confirmation No. 1709			
OTHE	R DOCUMENTS (Includ	ing Author, Title, Date,	Pertinent Pages, Etc.)		
41		lation and sequence analy r gene," <i>EMBO J.</i> , 1983 ,	rsis of the human corticotrophin- 2(5), 775-779		
42	sexual receptivity in the	female rat," Nature, Septe	sing factor is a potent inhibitor of ember 15, 1983, 305, 232-235		
43	rats," Nature, May 27, 19	Effect of hypothalamus lesions on the presence of CRF- erminals in the median eminence and on the pituitary-adrenal			
44					
45	Yana				
46			ovine hypothalamic peptide that phin," Science, September 1981,		
47	Vita, N., et al., "Primary human brain corticotroph 335(1), 1-5	nin releasing factor recept	expression of mouse pituitary and ors," <i>FEBS</i> , November 1993 ,		
48	identification, autoradiog guanine nucleotides," En	graphic locatization, and radocrinology, 1988 , <i>122(2</i>			
49	responses to stress," Am.	J. Physiol., 1987, 253, G			
50		•	gh-affinity pituitary receptors for hys. Res. Comm., January 27, 1983,		
EXAMINER		DATE CON	SIDERED		



OCT 2 0 2003

TECH CENTER 1600/2900

Sheet 6 of 7

List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce				Docket No. Application No. BMS-0891/PH-7345-A 09/995,159			
				Applicant James R. McCarthy, et al.			
				Filing Date Group November 27, 2001 1624			
				Confirmation No. 1709			
		U.	S. PATENT	DOCUMENTS	1		
Examiner Initial		Document No.	Date	Name	Class	Subclass	
	51	5,063,245	11/05/91	Abreu, et al.	514	404	
	52	5,464,847	11/07/95	Courtemanche, et al.	514	342	
	53	4,605,642	08/12/86	Rivier, et al.	514	12	
54 US 6,352,990 B1 03/0		03/05/02	McCarthy	514	261		
				·			
		FORE	CIGN PATE	ENT DOCUMENTS			
Examiner					Tra	nslation	
Initial		Document No.	Date	Country	YES	NO	
	55	41399/93	01/06/94	Australia			
	56	0 773 023 A1	05/14/97	ЕРО			
	57	0 778 277 A1	06/11/97	EPO			
	58	0 812 831 A1	12/17/97	EPO			
	59	WO 94/13676	06/23/94	PCT			
EXAMINE	R		···	DATE CONSIDERED			



OCT, 2 0 2003

TECH CENTER 1600/2900

Sheet 7 of 7

List of Patent and Publications Cited by Applicant				Docket No. BMS-0891/PH-7345-A	Application 09/995,159	No.
				Applicant James R. McCarthy, et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date Group November 27, 2001 1624			
				Confirmation No. 1709		
•••	-	U.	S. PATEN	T DOCUMENTS		******
Examiner Initial		Document No.	Date	Name	Class	Subclass
		FOR	_ EIGN PATE	ENT DOCUMENTS	l	
Examiner Initial		Document No.	Date	Country	Tra YES	nslation NO
Illitiai	60	WO 94/13677	06/23/94	PCT	1 E S	NO
	61	WO 95/33750	12/14/95	PCT		
	62	WO 95/34563	12/21/95	PCT		
	63	WO 96/35689	11/14/96	PCT		
	64	WO 97/29109	08/14/97	PCT		
, ,	65	WO 98/08846	03/05/98	PCT		
	66	WO 98/08847	03/05/98	PCT		
	67	WO 98/03510	01/29/98	PCT		
	68	WO 98/35967	08/20/98	PCT		
					_	
EXAMINER	<u> </u>			DATE CONSIDERED		